Y-mAbs Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.9M
Doctors Paid
330
Transactions
1,447
2024 Total
$1.7M
Payment Breakdown by Category
Research$8.3M (93.2%)
Consulting$533,328 (6.0%)
Food & Beverage$28,192 (0.3%)
Travel$4,774 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.3M | 912 | 93.2% |
| Consulting Fee | $533,328 | 125 | 6.0% |
| Honoraria | $39,925 | 14 | 0.4% |
| Food and Beverage | $28,192 | 380 | 0.3% |
| Travel and Lodging | $4,774 | 12 | 0.1% |
| Grant | $2,500 | 3 | 0.0% |
| Entertainment | $24.35 | 1 | 0.0% |
Payments by Type
Research
$8.3M
912 transactions
General
$608,743
535 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| PHASE 1 TRIAL WITH GD2-SADA:177LU-DOTA DRUG COMPLEX IN PATIENTS WITH RECURRENT OR REFRACTORY METASTATIC SOLID TUMORS KNOWN TO EXPRESS GD2, INCLUDING SMALL CELL LUNG CANCER, SARCOMA AND MALIGNANT MELANOMA | $2.5M | 0 | 626 |
| NAXITAMAB ADDED TO INDUCTION FOR NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA | $1.0M | 0 | 4 |
| SAFETY AND CLINICAL ACTIVITY OF NIVATROTAMAB, AN ANTI GD2?CD3 BISPECIFIC ANTIBODY, IN RELAPSED/RECURRENT METASTATIC SMALL-CELL LUNG CANCER | $704,457 | 0 | 78 |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | $606,050 | 0 | 8 |
| SPONSORED RESEARCH AGREEMENT SK2020-1049 | $375,000 | 0 | 3 |
| SPONSORED RESEARCH AGREEMENT SK2020-1048 | $374,995 | 0 | 3 |
| MSK MOU | $302,725 | 0 | 6 |
| A MULTICENTER PHASE 2/3 TRIAL OF THE EFFICACY AND SAFETY OF INTRACEREBROVENTRICULAR RADIOIMMUNOTHERAPY USING 131I-OMBURTAMAB FOR NEUROBLASTOMA CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL METASTASES | $283,789 | 3 | 31 |
| PHASE II TRIAL OF 131 I-OMBURTAMAB IN COMBINATION WITH EXTERNAL BEAM RADIOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS AND OTHER SOLID TUMORS INVOLVING THE PERITONEUM | $278,252 | 0 | 9 |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | $219,155 | 0 | 1 |
| A PHASE II STUDY OF HUMANIZED MONOCLONAL ANTIBODY 3F8 (HU3F8) WITH GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN THE TREATMENT OF RECURRENT OSTEOSARCOMA | $206,323 | 0 | 10 |
| A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF 124I-OMBURTAMAB FOR PATIENTS WITH NON-PROGRESSIVE DIFFUSE PONTINE GLIOMAS PREVIOUSLY TREATED WITH EXTERNAL BEAM | $186,103 | 0 | 4 |
| SPONSORED RESEARCH AGREEMENT SK2019-0921 | $151,700 | 0 | 2 |
| PHASE I/II TRIAL OF A BIVALENT VACCINE WITH ESCALATING DOSES OF THE IMMUNOLOGICAL ADJUVANT OPT-821, IN COMBINATION WITH ORAL ?-GLUCAN FOR HIGH-RISK NEUROBLASTOMA | $151,363 | 0 | 6 |
| A Study of a Vaccine in Combination With Bglucan and GM CSF in People With Neuroblastoma | $151,363 | 0 | 6 |
| 177LU-DTPA-OMBURTAMAB RADIOIMMUNOTHERAPY FOR RECURRENT OR REFRACTORY MEDULLOBLASTOMA | $126,704 | 0 | 4 |
| Phase 1 trial with GD2-SADA:177Lu-DOTA Drug Complex in patients with recurrent or refractory metastatic solid tumors known to express GD2, including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma | $119,000 | 0 | 2 |
| TARGETING GD2 IN TRIPLE-NEGATIVE BREAST CANCER USING NAXITAMAB AND ACTIVATED NATURAL KILLER CELLS | $109,324 | 0 | 2 |
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION TRIAL OF CD33XCD3 BISPECIFIC ANTIBODY IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | $76,000 | 0 | 7 |
| Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastom | $63,000 | 0 | 1 |
| A PIVOTAL PHASE 2 TRIAL OF ANTIBODY NAXITAMAB (HU3F8) AND GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-CSF) IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH PRIMARY REFRACTORY DISEASE OR INCOMPLETE RESPONSE TO SALVAGE TREATMENT IN BONE AND/OR BONE MARROW | $61,544 | 3 | 53 |
| PHASE I STUDY OF INTRATHECAL RADIOIMMUNOTHERAPY USING I-8H9 FOR CENTRAL NERVOUS SYSTEM/LEPTOMENINGEAL NEOPLASMS | $60,882 | 0 | 10 |
| PHASE I/II STUDY OF HUMANIZED 3F8 BISPECIFIC ANTIBODY (HU3F8-BSAB) IN PATIENTS WITH RELAPSED/REFRACTORY NEUROBLASTOMA, OSTEOSARCOMA, AND OTHER GD2(+) SOLID TUMORS | $51,912 | 0 | 6 |
| A Phase I Trial of Intracerebroventricular 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis from Solid Tumors | $29,001 | 0 | 1 |
| A Phase I Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory Medulloblastoma | $21,514 | 0 | 1 |
| A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | $18,965 | 2 | 4 |
| A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma | $12,600 | 0 | 1 |
| PHASE II STUDY OF HU3F8, IRINOTECAN/TEMOZOLOMIDE AND SARGRAMOSTIM (HITS) CHEMOIMMUNOTHERAPY FOR HIGH-RISK NEUROBLASTOMA | $11,712 | 0 | 3 |
| HU3F8/GM-CSF IMMUNOTHERAPY PLUS ISOTRETINOIN FOR CONSOLIDATION OF FIRST REMISSION OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA: A PHASE II STUDY | $9,588 | 0 | 1 |
| PHASE I STUDY OF HUMANIZED 3F8 MONOCLONAL ANTIBODY (HU3F8) IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AND GD2-POSITIVE TUMORS | $8,895 | 0 | 8 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Hematology-Oncology | $157,332 | 86 | $1,829 |
| Student in an Organized Health Care Education/Training Program | $142,248 | 3 | $47,416 |
| Anatomic Pathology | $112,400 | 1 | $112,400 |
| Pediatrics | $85,029 | 118 | $720.58 |
| Specialist | $34,440 | 3 | $11,480 |
| Nuclear Medicine | $32,775 | 2 | $16,388 |
| Diagnostic Radiology | $23,228 | 4 | $5,807 |
| Internal Medicine | $15,061 | 4 | $3,765 |
| Hematology | $7,064 | 2 | $3,532 |
| Hematology & Oncology | $6,898 | 4 | $1,725 |
| Neurology | $3,450 | 1 | $3,450 |
| Family | $3,245 | 31 | $104.67 |
| Nurse Practitioner | $1,976 | 27 | $73.17 |
| Anesthesiology | $700.00 | 1 | $700.00 |
| Obstetrics & Gynecology | $700.00 | 1 | $700.00 |
| Physician Assistant | $582.07 | 14 | $41.58 |
| Registered Nurse | $565.17 | 9 | $62.80 |
| Emergency Medicine | $224.88 | 2 | $112.44 |
| Primary Care | $212.17 | 3 | $70.72 |
| Family Medicine | $206.76 | 2 | $103.38 |
| Medical | $125.00 | 1 | $125.00 |
| Urology | $125.00 | 1 | $125.00 |
| Adult Health | $122.74 | 1 | $122.74 |
| Nurse Anesthetist, Certified Registered | $114.70 | 1 | $114.70 |
| Oncology, Pediatrics | $109.37 | 1 | $109.37 |
| Licensed Practical Nurse | $85.07 | 1 | $85.07 |
| Midwife | $84.66 | 1 | $84.66 |
| Acute Care | $33.93 | 1 | $33.93 |
| Pediatrics, Critical Care | $25.56 | 1 | $25.56 |
| Surgical | $25.41 | 1 | $25.41 |
| Neurology with Special Qualifications in Child Neurology | $24.69 | 1 | $24.69 |
| Pediatric Endocrinology | $21.91 | 1 | $21.91 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Evgeniya Angelova, Md, Phd, MD, PHD | Student in an Organized Health Care Education/Training Program | Red Bank, NJ | $142,000 | $0 |
| Dr. Hatice Gur, Md, MD | Anatomic Pathology | Boston, MA | $112,400 | $0 |
| Steven Larson, Md, MD | Nuclear Medicine | New York, NY | $27,775 | $0 |
| Matthew Fletcher, M.d, M.D | Pediatric Hematology-Oncology | Dallas, TX | $20,035 | $0 |
| Dr. Daniel Pryma, Md, MD | Specialist | Philadelphia, PA | $17,398 | $0 |
| Jian Qin Yu, M.d, M.D | Specialist | Philadelphia, PA | $16,292 | $0 |
| Javier Oesterheld, Md, MD | Pediatrics | Charlotte, NC | $15,313 | $0 |
| Helen Nadel, Md, MD | Diagnostic Radiology | Palo Alto, CA | $15,275 | $0 |
| Dr. Anurag Agrawal, Md, MD | Pediatric Hematology-Oncology | Oakland, CA | $14,962 | $0 |
| Roland Chu, Md, MD | Pediatrics | Detroit, MI | $11,866 | $0 |
| Melissa Bear, M.d, M.D | Pediatric Hematology-Oncology | Indianapolis, IN | $11,436 | $0 |
| Sara Federico, Md, MD | Pediatrics | Memphis, TN | $10,068 | $0 |
| Dr. Mario Otto, M.d., Ph.d, M.D., PH.D | Pediatric Hematology-Oncology | Phoenix, AZ | $10,025 | $0 |
| Araz Marachelian, Md, MD | Pediatric Hematology-Oncology | Los Angeles, CA | $9,390 | $0 |
| Dr. Leonora Slatnick, M.d, M.D | Pediatric Hematology-Oncology | Aurora, CO | $9,018 | $0 |
| Jennifer Foster, Md, MD | Pediatric Hematology-Oncology | Houston, TX | $8,674 | $0 |
| Dr. Gayle Smink, M.d., M.p.h, M.D., M.P.H | Pediatric Hematology-Oncology | Hershey, PA | $7,860 | $0 |
| Holly Meany, Md, MD | Pediatric Hematology-Oncology | Washington, DC | $7,451 | $0 |
| Dr. Katherine Matthay, M.d, M.D | Hematology | San Francisco, CA | $7,050 | $0 |
| Ryan Murtagh, Md, MD | Diagnostic Radiology | El Segundo, CA | $6,813 | $0 |
| Gail Roboz, Md, MD | Internal Medicine | New York, NY | $6,750 | $0 |
| Giselle Saulnier Sholler, Md, MD | Pediatric Hematology-Oncology | Hershey, PA | $6,286 | $0 |
| Kim Kramer, Md, MD | Pediatric Hematology-Oncology | New York, NY | $5,900 | $0 |
| Erin Trovillion, Md, MD | Pediatrics | Charlotte, NC | $5,646 | $0 |
| Dr. Alissa Martin, Md, MD | Pediatrics | Detroit, MI | $5,612 | $0 |
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. has made $8.9M in payments to 330 healthcare providers, recorded across 1,447 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is DANYELZA ($2.4M).
Payments were distributed across 32 medical specialties. The top specialty by payment amount is Pediatric Hematology-Oncology ($157,332 to 86 doctors).
Payment categories include: Food & Beverage ($28,192), Consulting ($533,328), Research ($8.3M), Travel & Lodging ($4,774).
Y-mAbs Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.